The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via Getty Images

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.”

Dr. Navin Varadarajan is the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston. Photo via UH.edu

The NanoSTING-NS is also notable for its potential ability to end what Varadarajan calls “the endless cycle of boosting.” The way to do that, he explains, is to prevent the infection at its root. And theoretically, his lab’s invention could do that. But he cautions readers not to get too excited just yet.

The vaccine is currently in the phase of animal testing, though Varadarajan is hopeful that it could move to human samples in about a year.

The therapeutic can treat multiple respiratory viruses by using fat droplets to deliver the immune booster cGAMP.

“The ability to activate the innate immune system presents an attractive route to armoring humans against multiple respiratory viruses, viral variants and also minimizing transmission to vulnerable people,” says postdoctoral associate Ankita Leekha, first author on the paper that shares NanoSTING’s findings. “The advantage of NanoSTING is that only one dose is required, unlike the antivirals like Tamiflu that require 10 doses.”

Ankita Leekha is the first author on the paper that shares NanoSTING’s findings. Photo via UH.edu

Varadarajan puts it even more simply: “Just like we have Tylenol, just like you take aspirin, you feel like you have some symptoms, and you take it afterwards.”

Currently, he says that the partners with whom the lab is working towards commercialization are prioritizing the therapeutic over the vaccine. The reasons are clear. Varadarajan explains that, while we’ve now long had antibiotics to broadly combat infections, there hasn’t been anything like that to battle viruses. With its ability to target multiple viruses, NanoSTING could be that innovation.

“We activate the innate immune system. So our drug is not virus-specific. Our drug works by activating your own immune system, and that will then fight off different kinds of viruses,” he says.

A single product that treats everything from the common cold to COVID-19 by capitalizing on the patient’s own immune system could be closer than we realize.

The researchers hope to get the vaccine into human trials soon. Photo via UH.edu

What started as a way to bring natural cleaning products in from overseas has turned into a promising application for more sustainable agriculture solutions. Photo via Pexels

Houston entrepreneur brings natural, sustainable cleaning products to US for farm to table application

clean dream

When something is declared clean, one question invariably springs to mind: just how clean is clean?

Then it is, “What metrics decide what’s clean and what’s not?”

To answer those questions, one must abandon the subjective and delve into the scientific — and that’s where Clean Habits come in. The company has science on its side with Synbio, a patented cleaning formula that combines a unique blend of prebiotics and probiotics for their signature five-day clean.

“Actually, we are a synbiotic, which is a prebiotic and a probiotic fused together,” says Kristy Phillips, founder and CEO of Clean Habits. “And that's what gives us the five-day clean, and we also have the longest shelf life — three years — of any probiotic on the market.”

Phillips learned about the European product almost three months before the COVID-19 pandemic. She had heard of probiotics for gut health but had no idea about probiotic cleaning.

“When COVID actually hit, I went back and really started researching the manufacturer who is based in Europe and all of their pre- and probiotic cleaners,” remembers Phillips. “And I just found it to be so interesting that they were using natural probiotics from the dirt, from the soil, from Mother Earth. And they created this entire product line that they have been using for over 15 years. And they had so many clinical trials and hospital studies and university studies that were showing that these probiotic cleaners were working, and they were reducing bacteria, viruses, even viruses in air.

“Not only were they in the cleaning spray sector, but they were also already in water purification. They were in agriculture for animal house farming. They were doing a big trial in the subway station in Milan, putting the probiotics through a big HVAC system. And I just thought, there must be something here.”

Kristy Phillips is the founder and CEO of Clean Habits. Photo via LinkedIn

Phillips was right. After reaching out to the manufacturer, she asked if they had a distributor here in the United States. They didn't.

“Since they didn’t have a distributor here in the U.S., I got the products and tried them out for myself,” says Phillips. “They were chemical-free, non-toxic and eco-friendly and after comparing them side-by-side with the commercial cleaners we all grew up with like the Lysols, bleach, and 409s, I found that the probiotic cleaners not only worked on surface areas to remove bad bacteria and germs, they continued to work for up to five full days at 100 percent.

“The commercial cleaners did kill 99.99 percent of all bacteria and germs, but they only did it for 30 minutes. And then the bacteria and germs start to grow back. And I am like, you know, nobody tells you that in their marketing. So that is what started my journey on the probiotics and creating a line to bring to the market here in the United States.”

Phillips soon realized that her goal was easier said than done.

“I think the U.S. market is one of the hardest to break into,” says the Houston native. “Trying to launch a brand-new product in the United States, in the cleaning sector, you do have to deal with the FDA and the EPA, there is a big game that you must play. And then you do go up against the big boys, like the Johnson and Johnson's of the world. Everybody is so used to chemical cleaning. And to go and try to change that industry and disrupt it, that can be tough for people.

“And at the time, I felt like it was insane because everyone was living in their house due to COVID and continuing to use commercial cleaners that are backed with chemicals. They were all breathing that in. I felt that was doing us all an injustice, especially when you have these probiotics that are natural, non-toxic, non-chemical and safe to breathe. It does change the game.”

Once Phillips noticed that she was not alone, with companies like Jessica Alba’s The Honest Company and Mrs. Meyer’s with their plant-based cleaning products, she forged full speed ahead with Clean Habits.

Now, more than three years later, her company is making a significant impact.

“I said, OK, I’m not crazy here, I must be on the right path,” says Phillips. “With people starting to recognize that there is a better way to clean, we began to get into retailers like Kroger. Right now, we are in the process of on-boarding with Walmart and are in talks with CVS, Whole Foods, and Costco.”

The biggest signal to Phillips that the word was out on Clean Habits came in the form of a potential celebrity endorsement.

“Howie Mandel, who is a certified germaphobe, reached out to us a couple of weeks ago,” says Phillips, who before her mission to clean up the world, was a producer of reality television. “We are about to do a big campaign with him and the Clean Habits line. People know Howie Mandel. So, he is definitely going to bring more awareness to our brand, which will allow us to start a big, heavy push and hopefully we can just capitalize on it and go from there.”

Moving forward, Phillips’ vision for Clean Habits will extend beyond just traditional cleaning products. She sees that she can also have an impact on the industrial and commercial side of things.

“Right now, we are doing testing in agriculture, and this is something that our manufacturers in Europe have already done and they have been extremely successful with it,” says Phillips. “The goal is to see if we could reduce the use of pesticides in farming and replace it with just misting and spraying with the probiotics.

“We already know that by incorporating the probiotics throughout water systems, that we can actually clean the water and take it back to 100 percent natural water or pure water. We can get rid of E. coli, MRSA, staph. And so, we are going to start working with the state of Texas and into animal house cleaning and farming and cleaning their water.”

Additionally, Clean Habits already has research that proves that by incorporating the probiotics, they can start eliminating the bird flu, which affected a lot of Texas chickens recently to where over 350,000 of them had to be put down.

“We’re really trying to change the faith there in agriculture,” says Phillips. “I mean, to me, it's amazing because when I first started this, I was just trying to launch some cleaning supplies, which is fantastic, but this product is so much more than a multi-purpose cleaning spray, your floor cleaner, your drain cleaner or your laundry detergent. This goes into cleaning water, which is everyone's basic right to have clean water. And the fact that we can do it by using these probiotics, to me, my little brain can't compute that part of it.

“And then when we really did start looking into the agriculture and how, by incorporating the probiotics into the animal house, the cleaning of the water, and putting it into their housing system, that we can reduce methane gas by 41 percent. That is huge. This can profoundly change and revolutionize industries. And to be a part of that, and I am so excited.”

While COVID-19 cases are not expected to surge this winter like 2020 and 2021, there are some things you can implement within your business to make sure employees stay healthy through the holidays. Photo via Getty Images

Houston expert: How to keep your workforce healthy this holiday season

guest column

Since the coronavirus pandemic shut down the world economy in March 2020, it has not been business as usual. Last winter presented new challenges to small businesses as the Omicron variant caused a surge in cases and hospitalizations throughout the country, interrupting business once again.

Center for Disease Control (CDC) Director Dr. Anthony Fauci predicted less of a surge this winter than in 2020 and 2021 in a recent White House briefing. The CDC also reports the 32 percent of Americans who remain unvaccinated, whether for personal or medical reasons, remain at greater risk. Cases are not yet trending upward in Texas at a pace for concern, but neighboring New Mexico is experiencing an upswing, as is Arizona, according to data from the Mayo Clinic.

That raises the question, yet again, of how to address the issue with employees nearly three years into the pandemic. Businesses need to evaluate their plans now for a likely increase in coronavirus cases.

Evaluate risk factors

Each small business faces a different risk from a coronavirus surge based on its operations, employees and business model. Unlike bigger corporations, small businesses cannot easily reallocate staff when the coronavirus spreads within the workplace. If an infection spreads to a majority of the team, leanly staffed businesses may need to shut down until employees can return to work.

For businesses producing or distributing consumer or industrial goods, a coronavirus surge in a factory or warehouse could further impact delivery times or disrupt the supply chain. Likewise, independent medical practices, spas or gyms with daily in-person contact could face major impacts in the event of coronavirus spreading between employees and clients. On the other hand, a client services agency like a law firm with a hybrid schedule may face less of a risk, provided sick employees feel well enough to work from home.

Risk will also vary based on vaccination rates, age and health of staff. Employers should be careful to protect employee’s privacy but asking whether an employee is vaccinated does not violate any laws if the question is limited to a yes-or-no answer, according to the U.S. Equal Employment Opportunity Commission. Federal law also does not prohibit employers from requiring all employees to be vaccinated in some circumstances but employers who wish to explore that option should consult with legal counsel to understand the risks.

Finally, businesses need to understand their community risk factors. Find out where weekly coronavirus data is reported within the region and assign responsibility to HR for tracking this data. If cases begin to peak, that could signal growing risk to the business and workers.

Based on the evaluation of risk factors to employees and business operations, determine how a possible surge could impact profitability. If possible, crunch the numbers on revenue and losses for a clear understanding of the financial ramifications. This data will help guide protocols.

Address preventive measures

In the early days of the pandemic, many businesses introduced requirements for employees to test regularly or remain home if experiencing symptoms of the coronavirus. While some businesses have discontinued these policies, they represent a helpful starting point for preventive protocols to implement during another surge.

Businesses who face a significant risk from a coronavirus surge may wish to introduce regular testing at once-a-week intervals, regardless of whether employee show coronavirus symptoms. Communicate to employees about why these protocols are necessary. In July 2022, Pew Research Center found only 41 percent of Americans view the coronavirus as a major threat to public health, down from 67 percent in July 2020. That means employees may take fewer precautions in their own lives and benefit from a reminder of the potential coronavirus impacts to business.

Staggered schedules can further lower the risk of a coronavirus breakout in the workplace, especially for the largest teams on staff. A business with a hybrid remote work policy may divide teams into “pods” where employees only come into the workplace on the same day as other workers in their pod. This approach can contain the potential coronavirus spread to the individuals within the pod while allowing in-person collaboration to continue.

It is important to keep in mind these policies present their own costs in the form of coronavirus test kits, if provided to employees by the business, the cost of employees’ time and possible reduced productivity. Considering these tradeoffs, entirely remote startups or small businesses with less risk of spreading coronavirus between teams may decide against mandatory testing and staggered schedules. Businesses who make that decision should carefully monitor coronavirus data in their communities in case circumstances should change.

Set protocols for illnesses

Regardless of mandatory testing and staggered schedules, all small businesses should put coronavirus policies in place, including how to respond with symptoms present and for those who test positive, but may not have symptoms. When setting policies for those who test positive or someone in their household tests positive, it is important to get the latest information on quarantines from the CDC and communicate these policies clearly with employees.

If vaccination status is unknown, set a rule applying to everyone. Policies to prevent a coronavirus case from spreading include a requirement for exposed employees to work remotely for the quarantine period or wear a mask and socially distance in the workplace. While small businesses and startups often take pride in their flexible approaches, coronavirus policies should be fair and standardized for all.

The worst of the pandemic may be over, and by planning for the likelihood of a winter coronavirus surge, businesses can help ensure it stays that way.

------
Jill Chapman is a director of early talent programs with Insperity, a leading provider of human resources and business performance solutions.

A team out of the engineering school at Rice University has created a technology for real-time wastewater monitoring. Photo via rice.edu

Houston research team snags $2M grant for virus sensing tech

money moves

A team of researchers from Rice University have received a $2 million grant to develop a unique technology that speeds up the analysis of wastewater for viruses from hours to seconds.

The team is based out of Rice’s George R. Brown School of Engineering and led by Rafael Verduzco, associate chair and a professor of chemical and biomolecular engineering and of materials science and nanoengineering. The four-year grant from the National Science Foundation will support the development of the technology, which includes wastewater-testing bioelectric sensors that deliver immediate notice of presence of viruses like SARS-CoV-2, which causes COVID-19, according to a news release from Rice.

The research project — with its partners at the Houston Health Department — have already developed water testing procedures and have analyzed samples from locations around the city. The current process includes taking samples and transferring them to Rice for analysis, but the new technology would be able to monitor systems onsite and instantly. The parties involved with this work are also collaborating with the Centers for Disease Control and Prevention Center of Excellence for wastewater epidemiology that was announced in August.

“Monitoring wastewater for COVID has been pretty effective as a way to get an idea of where we are as a population,” says Verduzco in the release. “But the way it’s done is you have to sample it, you have to do a PCR test and there’s a delay. Our selling point was to get real-time, continuous monitoring to see just how much of this virus is in the wastewater.”

The grant's co-principal investigators include Jonathan Silberg, the Stewart Memorial Professor of BioSciences and director of the Systems, Synthetic and Physical Biology Ph.D. program, and Caroline Ajo-Franklin, a professor of biosciences. Co-investigators also include Lauren Stadler, an assistant professor of civil and environmental engineering, and Kirstin Matthews, a fellow at the Baker Institute for Public Policy.

“These are engineered microbes we’re putting into wastewater, and even though they’re encapsulated, we want to know if there are concerns from health authorities and the general population,” Verduzco said. “Kirstin’s role is to look at the policy side, and also gauge public reaction and educate people about what it means when we talk about engineered bacteria.”

Rafael Verduzco is leading the research and development. Photo by Jeff Fitlow/Rice University

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

2 UH projects named finalists for $50M fund to shape future of Gulf Coast

Looking to the Future

Two University of Houston science projects have been selected as finalists for the Gulf Futures Challenge, which will award a total of $50 million to develop ideas that help benefit the Gulf Coast.

Sponsored by the National Academies of Science, Engineering and Medicine’s Gulf Coast Research Program and Lever for Change, the competition is designed to spark innovation around problems in the Gulf Coast, such as rising sea levels, pollution, energy security, and community resiliency. The two UH projects beat out 162 entries from organizations based in Alabama, Florida, Louisiana, Mississippi, and Texas.

“Being named a finalist for this highly competitive grant underscores the University of Houston’s role as a leading research institution committed to addressing the most pressing challenges facing our region,” said Claudia Neuhauser, vice president for research at UH.

“This opportunity affirms the strength of our faculty and researchers and highlights UH’s capacity to deliver innovative solutions that will ensure the long-term stability and resilience of the Gulf Coast.”

One project, spearheaded by the UH Repurposing Offshore Infrastructure for Continued Energy (ROICE) program, is studying ways to use decommissioned oil rig platforms in the Gulf of Mexico as both clean energy hydrogen power generators as well a marine habitats. There are currently thousands of such platforms in the Gulf.

The other project involves the innovative recycling of wind turbines into seawall and coastal habitats. Broken and abandoned wind turbine blades have traditionally been thought to be non-recyclable and end up taking up incredible space in landfills. Headed by a partnership between UH, Tulane University, the University of Texas Health Science Center at Houston, the city of Galveston and other organizations, this initiative could vastly reduce the waste associated with wind farm technology.

wind turbine recycled for Gulf Coast seawall. Wind turbines would be repurposed into seawalls and more. Courtesy rendering

"Coastal communities face escalating threats from climate change — land erosion, structural corrosion, property damage and negative health impacts,” said Gangbing Song, Moores Professor of Mechanical and Aerospace Engineering at UH and the lead investigator for both projects.

“Leveraging the durability and anti-corrosive properties of these of decommissioned wind turbine blades, we will build coastal structures, improve green spaces and advance the resilience and health of Gulf Coast communities through integrated research, education and outreach.”

The two projects have received a development grant of $300,000 as a prize for making it to the finals. When the winner are announced in early 2026, two of the projects will net $20 million each to bring their vision to life, with the rest earning a consolation prize of $875,000, in additional project support.

In the event that UH doesn't grab the grand prize, the school's scientific innovation will earn a guaranteed $1.75 million for the betterment of the Gulf Coast.

---

This article originally appeared on CultureMap.com.

Kids, kicks and connectivity: Xfinity makes soccer a shared experience

The Beautiful Game

For soccer mom Lana Chase, weekends were a whirlwind of cleats, carpooling, and cheering from the sidelines. Now that her daughter Miah graduated high school in May, the Chase Family’s love for the game hasn't stopped. It's shifted to their living room, where Comcast’s new Xfinity streaming platform brings the global game home.

“We’re a soccer family through and through,” says Chase. “Miah played soccer from about age 8 until 16, and we love the World Cup! Xfinity makes it easy for all of us to watch what we love together.”

One platform, every goal

Xfinity's new World Soccer Ticket package eliminates the chaos of juggling apps, subscriptions, or subpar streams. Families can now enjoy more than 1,500 matches from across the globe.

With parental controls, age-appropriate content, and smart recommendations, Xfinity turns soccer into family-friendly entertainment. Whether it’s a weekend watch party or a quiet school night, the platform adapts to every household’s rhythm.

“Figuring out where to watch your favorite team or match is often a painful game of chance. Now, with World Soccer Ticket, there’s no better way to watch the beautiful game than with Xfinity,” says Jon Gieselman, chief growth officer for Comcast's connectivity & platforms. “It’s easy, we did the work for our customers and pulled together the most coveted leagues and tournaments – from Premier League, LALIGA and Champions League to the World Cup – and put them in one place. We added some magic to the experience, with innovations like Multiview, 4K, and Sports Zone all easily accessible with one simple click or voice command.”

World Cup in Houston

With the 2026 World Cup on the horizon, the timing couldn't have been better. The world tournament will be the largest Spanish-language coverage ever offered by Telemundo, powered by Comcast NBCUniversal's technology, storytelling, and scale.

Telemundo and Peacock hold the exclusive Spanish language rights to "el Mundial," including all 104 matches streaming live on Peacock, with 92 matches airing on Telemundo and 12 on Universo. Live crews will cover every event in all 16 host cities, including Houston.

Xfinity customers will have access to pregame, halftime, and postgame coverage with unprecedented immersive experiences. The 2026 World Cup will be the most exciting event of the summer.

"We know other soccer families who watch matches with their little brothers and sisters. It’s not just a game, it’s family time. It's an even bigger deal with the tournament being just down the road in Houston next year,” Chase adds.

Comcast’s AI-powered platform personalizes the viewing experience, recommending matches and highlights based on each family member’s preferences.

World Soccer Ticket is available for an all-in monthly price of $85. It includes nearly 60 broadcast, cable news, and English- and Spanish-language sports channels, and a subscription to Peacock Premium so customers can enjoy a huge collection of movies, shows, news, and other live sports alongside all their favorite soccer programming.

Subscribe to World Soccer Ticket here.

Houston digital health platform Koda closes $7 million funding round

fresh funding

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.